Furthermore, the association of genes like ORC1 with immune checkpoint genes (e.g., CD274 and LAG3) integrates CRC biology with the immune microenvironment, suggesting that multi-modal therapeutic approaches targeting genetic, epigenetic, and immune facets may offer a holistic and potentially more effective treatment strategy against CRC. The gene discussed is ORC1; the disease is colorectal carcinoma.